Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage pharmaceutical company developing proprietary therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system. The ARTL news feed on Stock Titan aggregates company announcements, scientific updates, financing transactions, and regulatory disclosures that shape the outlook for its drug development programs.
Investors and observers following Artelo’s news can track progress across a diversified pipeline that includes ART27.13 for cancer anorexia and weight loss, ART26.12 as a Fatty Acid Binding Protein 5 (FABP5) inhibitor for chemotherapy-induced peripheral neuropathy and other potential indications, and ART12.11, a patented cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). Company press releases highlight interim clinical data from the Cancer Appetite Recovery Study (CAReS), Phase 1 results for ART26.12, and preclinical findings supporting the therapeutic potential of FABP inhibition and pharmaceutical-grade CBD formulations.
The ARTL news stream also features peer-reviewed publication announcements, conference presentations at oncology and cannabinoid-focused meetings, and corporate developments such as executive appointments, cooperation agreements with shareholders, and capital-raising activities via public offerings, private placements, and at-the-market programs. Regulatory and listing-related updates, including communications about Nasdaq listing compliance, are disclosed through Form 8-K filings and associated press releases.
By reviewing Artelo Biosciences news on this page, readers can monitor key milestones in its clinical trials, scientific validation of its FABP and CBD platforms, and corporate actions that influence its financial and strategic position. Bookmark this feed to follow how Artelo’s lipid-signaling and endocannabinoid-targeted programs evolve through clinical, scientific, and capital markets events over time.
Artelo Biosciences (NASDAQ: ARTL) announced the appointment of Tamara A. Seymour, CPA, to its board of directors. Ms. Seymour brings over 30 years of experience in corporate finance within the biotech sector, having successfully raised over $250 million in funding. Her background includes serving as CFO for various public and venture-backed companies, along with expertise in clinical development and commercialization. The board believes her insights will be crucial for Artelo's growth as it seeks to advance its therapeutic programs targeting lipid-signaling pathways.
Artelo Biosciences (NASDAQ: ARTL) will present at the H.C. Wainwright Life Sciences Conference, scheduled for March 9-10, 2021. Gregory Gorgas, CEO, will provide insights on the company's development of therapeutics targeting the endocannabinoid system. The presentation will be available on-demand from March 9 at 7:00 AM Eastern Time on the conference platform. Additionally, Artelo's management will hold one-on-one meetings with qualified investors during the event, highlighting its focus on addressing unmet needs in various diseases.
Artelo Biosciences (NASDAQ: ARTL) announced promising findings from research highlighting the co-administration of cannabidiol (CBD) and tetramethylpyrazine (TMP) in cancer cell models. Conducted by experts from the University of Nottingham, the study suggests enhanced anti-cancer effects through synergistic interactions between the two compounds, although a slight reduction in CBD's anti-migration effect was noted. Artelo aims for further in vivo research and has secured a composition of matter patent, opening opportunities for clinical approval and market exclusivity for its CBD:TMP cocrystal program.
Artelo Biosciences (NASDAQ: ARTL) has appointed Andrew Yates, Ph.D., as Senior VP and Chief Scientific Officer, effective immediately. Yates brings extensive experience from AstraZeneca, where he played key roles in drug development and strategy. He will lead the R&D efforts and engage with the Scientific Advisory Board, enhancing Artelo's clinical development initiatives, particularly for ART27.13, aimed at addressing cancer-related anorexia. His appointment is expected to strengthen the company's capabilities in developing therapies for various conditions, including PTSD and pain.
Artelo Biosciences (NASDAQ: ARTL) announced the exercise of warrants from its October 2020 financing, resulting in net proceeds of approximately $3 million. This strengthens the company's balance sheet, leading to a pro-forma cash balance of $10.4 million as of November 30, 2020. The capital raised will be utilized to advance the company’s product development aimed at addressing unmet needs in various diseases, including cancer and pain.
Artelo Biosciences (NASDAQ: ARTL) will present at the LSX World Congress virtually from February 1-5, 2021. The presentation will be available on-demand to registered attendees until February 28, 2021. This event brings together key executives in healthcare and life sciences, providing a platform for investment and strategic discussions. Artelo focuses on therapeutics targeting the endocannabinoid system, addressing conditions like cancer and pain. More details can be found at their website.
Artelo Biosciences (ARTL) announced the receipt of Clinical Trials Authorization for its Cancer Appetite Recovery Study (CAReS) of ART27.13 in the UK. This Phase I/II trial targets cancer patients suffering from anorexia, addressing a significant unmet medical need. The company also secured a Mitacs Accelerate grant to further develop its ART26.12 program, exploring its potential in treating anxiety disorders. Financially, ARTL reported a net loss of $1.43 million for Q1 FY2021, with operating expenses slightly rising to $1.44 million.
Artelo Biosciences (NASDAQ: ARTL) announced its participation in the H.C. Wainwright BioConnect 2021 Conference, scheduled for January 11-14, 2021. The presentation will be available on-demand starting January 11 at 6:00 a.m. EDT and accessible for 90 days. Artelo is focused on developing therapeutics that modulate the endocannabinoid system to address unmet medical needs in conditions such as cancer, PTSD, and pain. The company is based in San Diego and is advancing a portfolio of product candidates aimed at various diseases.
Artelo Biosciences (NASDAQ: ARTL) has filed a composition of matter patent application with the UK Patent Office for a new solid dosage formulation related to its lead clinical program, ART27.13. This formulation aims to treat cancer patients suffering from anorexia. The company has received Clinical Trial Authorization for its Cancer Appetite Recovery Study (CAReS) and plans to begin enrollment by year-end 2020. If allowed, the patent application is expected to secure exclusivity for ART27.13 through 2041.
Artelo Biosciences (NASDAQ: ARTL) announced its participation in the 13th Annual LD Micro Main Event investor conference on December 15 at 9:40 a.m. PST. Gregory D. Gorgas, President and CEO, will present to a live virtual audience. The conference format includes a 10-minute presentation followed by a Q&A session. The Main Event takes place on December 14-15 on the Sequire Virtual Events platform. Artelo is focused on developing therapeutics targeting the endocannabinoid system, addressing unmet medical needs in various conditions such as cancer and pain.